|
WO2013076222A1
|
|
Differential annexin a3 measurements of serum and blood derivatives or fractions thereof for the diagnosis of prostate cancer
|
|
WO2012127030A1
|
|
Arylpiperazines as neuroprotective agents
|
|
WO2010084150A1
|
|
Diagnostic method for detecting neurodegenerative diseases
|
|
US2011263574A1
|
|
Pirenzepine as otoprotective agent
|
|
WO2010081823A1
|
|
Pirenzepine as otoprotective agent
|
|
CN102164964A
|
|
Novel antibodies recognizing native annexin A3
|
|
WO2009146915A2
|
|
Protein biomarkers for in vitro testing of developmental toxicity and embryotoxicity of chemical substances
|
|
WO2009062750A2
|
|
Active soluble post-translationally modified neuregulin isoforms
|
|
WO2008125262A1
|
|
Autoimmune regulation of prostate cancer by annexin a3
|
|
US2009318354A1
|
|
Use of at least one isoform of progesterone receptor membrane component 1 (PGRMC1)
|
|
EP2024748A2
|
|
Monoclonal anti-annexin a3 antibodies for the detection of prostate carcinoma
|
|
CN101501501A
|
|
Monoclonal anti-annexin A3 antibodies for the detection of prostate carcinoma
|
|
EP1906185A1
|
|
Use of at least one isoform of progesterone receptor membrane component 1 (PGRMC1)
|
|
WO2006108666A1
|
|
Mefloquine, nelfinavir and saquinavir as novel agents for neurodegenerative and (neuro-) inflammatory diseases
|
|
EP1824495A2
|
|
Finasteride, dutasteride and related compounds for preventing/treating neurologically-associated disorders
|
|
EP1724586A2
|
|
Annexin for cancer risk assessment
|
|
EP1767944A1
|
|
Phosphorylated or non-phosphorylated mPR as diagnostic marker or therapeutic target
|
|
CA2573674A1
|
|
Muscarinic antagonists with parp and sir modulating activity as agents for inflammatory diseases
|
|
CN101005844A
|
|
Muscarinic antagonists with PARP and SIR modulatng activity as agents for inflammatory diseases
|
|
EP1724585A1
|
|
Annexin for cancer risk assessment
|
